Search Results - "BARNATHAN, Elliot S"

CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab by Raghu, Ganesh, Martinez, Fernando J, Brown, Kevin K, Costabel, Ulrich, Cottin, Vincent, Wells, Athol U, Lancaster, Lisa, Gibson, Kevin F, Haddad, Tarik, Agarwal, Prasheen, Mack, Michael, Dasgupta, Bidisha, Nnane, Ivo P, Flavin, Susan K, Barnathan, Elliot S

“…The objective of this study was to determine the safety and efficacy of carlumab in the treatment of idiopathic pulmonary fibrosis (IPF).A phase 2, randomised,…”
Get full text

Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study by Spyropoulos, Alex C., Lipardi, Concetta, Xu, Jianfeng, Lu, Wentao, Suh, Eunyoung, Yuan, Zhong, Levitan, Bennett, Sugarmann, Chiara, De Sanctis, Yoriko, Spiro, Theodore E., Barnathan, Elliot S., Raskob, Gary E.

“…Acutely ill medical patients are at risk of venous thromboembolism (VTE) and VTE-related mortality during hospitalization and posthospital discharge, but…”
Get full text

Airway Inflammation and Illness Severity in Response to Experimental Rhinovirus Infection in Asthma by Zhu, Jie, MD, PhD, Message, Simon D., MD, PhD, Qiu, Yusheng, MD, PhD, Mallia, Patrick, MD, PhD, Kebadze, Tatiana, MD, Contoli, Marco, MD, Ward, Christine K., PhD, Barnathan, Elliot S., MD, Mascelli, Mary Ann, PhD, Kon, Onn M., MD, Papi, Alberto, MD, FCCP, Stanciu, Luminita A., MD, PhD, Jeffery, Peter K., PhD, DSc, Johnston, Sebastian L., PhD

“…Background The nature of bronchial mucosal inflammation and its physiologic and clinical significance in rhinovirus-induced asthma exacerbations is unclear. We…”
Get full text

Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients by Silkoff, Philip E., MD, Laviolette, Michel, MD, Singh, Dave, MD, FitzGerald, J. Mark, MD, Kelsen, Steven, MD, Backer, Vibeke, MD, Porsbjerg, Celeste M., MD, Girodet, Pierre-Olivier, MD, Berger, Patrick, MD, Kline, Joel N., MD, Chupp, Geoffrey, MD, Susulic, Vedrana S., PhD, Barnathan, Elliot S., MD, Baribaud, Frédéric, PhD, Loza, Matthew J., PhD

“…Background The Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study profiled patients with mild, moderate, and severe asthma and nonatopic…”
Get full text

The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease by Rennard, Stephen I, Fogarty, Charles, Kelsen, Steven, Long, William, Ramsdell, Joe, Allison, James, Mahler, Donald, Saadeh, Constantine, Siler, Thomas, Snell, Phillip, Korenblat, Phillip, Smith, William, Kaye, Mitchell, Mandel, Michael, Andrews, Charles, Prabhu, Rachakonda, Donohue, James F, Watt, Rosemary, Lo, Kim Hung, Schlenker-Herceg, Rozsa, Barnathan, Elliot S, Murray, John, on behalf of COPD Investigators

“…Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-related, inflammatory lung disease in which tumor necrosis factor-alpha is overexpressed…”
Get full text

Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial by Yuan, Zhong, Levitan, Bennett, Deng, Hsiaowei, Szarek, Michael, Bauersachs, Rupert M, Berkowitz, Scott D, Haskell, Lloyd, Barnathan, Elliot S, Bonaca, Marc P

“…The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery…”
Get full text

Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients by Raskob, Gary E, Spyropoulos, Alex C, Cohen, Alexander T, Weitz, Jeffrey I, Ageno, Walter, De Sanctis, Yoriko, Lu, Wentao, Xu, Jianfeng, Albanese, John, Sugarmann, Chiara, Weber, Traci, Lipardi, Concetta, Spiro, Theodore E, Barnathan, Elliot S

“…Background Asymptomatic proximal deep vein thrombosis (DVT) is an end point frequently used to evaluate the efficacy of anticoagulant thromboprophylaxis in…”
Get full text

Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure by Judson, Marc A, Mack, Michael, Beaumont, Jennifer L, Watt, Rosemary, Barnathan, Elliot S, Victorson, David E

“…Patient-reported outcome (PRO) measures have been developed to measure symptoms and other aspects of health-related quality of life. The Sarcoidosis Assessment…”
Get full text

Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER by Raskob, Gary E, Spyropoulos, Alex C, Spiro, Theodore E, Lu, Wentao, Yuan, Zhong, Levitan, Bennett, Suh, Eunyoung, Barnathan, Elliot S

“…Background Thromboprophylaxis extended after hospital discharge in medically ill patients currently is not recommended by practice guidelines because of…”
Get full text

A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma by Kollmeier, Alexa P., Barnathan, Elliot S., O'Brien, Christopher, Chen, Bin, Xia, Yichuan (Karen), Zhou, Bei, Loza, Matthew J., Silkoff, Philip E., Ge, Michelle, Thurmond, Robin L.

“…Data from preclinical and clinical studies support the evaluation of histamine 4 receptor antagonists in the treatment of asthma. Toreforant is a selective…”
Get full text

Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC) by Pawlowski, Colin, Wagner, Tyler, Puranik, Arjun, Murugadoss, Karthik, Loscalzo, Liam, Venkatakrishnan, A J, Pruthi, Rajiv K, Houghton, Damon E, O'Horo, John C, Morice, 2nd, William G, Williams, Amy W, Gores, Gregory J, Halamka, John, Badley, Andrew D, Barnathan, Elliot S, Makimura, Hideo, Khan, Najat, Soundararajan, Venky

“…Temporal inference from laboratory testing results and triangulation with clinical outcomes extracted from unstructured electronic health record (EHR) provider…”
Get full text

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness by Raskob, Gary E., Ageno, Walter, Albers, Gregory, Elliott, C. Gregory, Halperin, Jonathan, Maynard, Gregory, Steg, Philippe Gabriel, Weitz, Jeffrey I., Albanese, John, Yuan, Zhong, Levitan, Bennett, Lu, Wentao, Suh, Eun Young, Spiro, Theodore, Lipardi, Concetta, Barnathan, Elliot S., Spyropoulos, Alex C.

“…Background Venous thromboembolism (VTE) often occurs after hospitalization in medically ill patients, but the population benefit–risk of extended…”
Get full text

Molecular profiling and gene expression analysis in cutaneous sarcoidosis: The role of interleukin-12, interleukin-23, and the T-helper 17 pathway by Judson, Marc A., MD, Marchell, Richard M., MD, Mascelli, MaryAnn, PhD, Piantone, Alexa, PharmD, Barnathan, Elliot S., MD, Petty, Kevin J., MD, Chen, Dion, PhD, Fan, Hongtao, PhD, Grund, Heidi, RN, Ma, Keying, PhD, Baribaud, Frédéric, PhD, Brodmerkel, Carrie, PhD

“…Background Cutaneous sarcoidosis (CS) skin provides relatively noninvasive access to granulomatous sarcoidosis tissue. Objective We sought to explore the role…”
Get full text

Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals by Herrmann, Howard C., MD, Lu, Jiandong, MD, Brodie, Bruce R., MD, Armstrong, Paul W., MD, Montalescot, Gilles, MD, PhD, Betriu, Amadeo, MD, Neuman, Franz-Joseph, MD, Effron, Mark B., MD, Barnathan, Elliot S., MD, Topol, Eric J., MD, Ellis, Stephen G., MD

“…Objectives We hypothesized that patients most likely to benefit would be those at high risk with a shorter duration of acute ischemia and who required transfer…”
Get full text

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis by Lipardi, Concetta, Elliott, C. Gregory, Sugarmann, Chiara L., Haskell, Lloyd, Spyropoulos, Alex C., Raskob, Gary E., Xu, Jianfeng, Lu, Wentao, Marsigliano, Jessica, Spiro, Theodore, Yuan, Zhong, Wu, Shujian, Barnathan, Elliot S.

“…Background: Bronchiectasis is a chronic inflammation of the bronchi with recurrent infections and hemoptysis. The MAGELLAN study compared oral rivaroxaban, 10…”
Get full text

Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study by Spyropoulos, Alex C., Raskob, Gary E., Spiro, Theodore E., Lu, Wentao, De Sanctis, Yoriko, Albanese, John, Mebazaa, Alexandre, Barnathan, Elliot S.

“…Abstract This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital…”
Get full text

Hospital-based use of thromboprophylaxis in patients with COVID-19 by Spyropoulos, Alex C, Ageno, Walter, Barnathan, Elliot S

“…In a case series from China,2 increased D-dimer concentration at time of admission to hospital (>1 μg/mL) was associated with a risk of in-hospital mortality…”
Get full text

Inflammatory Profile and Response to Anti-Tumor Necrosis Factor Therapy in Patients with Chronic Pulmonary Sarcoidosis by Loza, Matthew J, Brodmerkel, Carrie, Du Bois, Roland M, Judson, Marc A, Costabel, Ulrich, Drent, Marjolein, Kavuru, Mani, Flavin, Susan, Lo, Kim Hung, Barnathan, Elliot S, Baughman, Robert P

“…Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial by Spyropoulos, Alex C., Goldin, Mark, Ageno, Walter, Albers, Gregory W., Elliott, C. Gregory, Hiatt, William R., Halperin, Jonathan L., Maynard, Gregory, Steg, P. Gabriel, Weitz, Jeffrey I., Spiro, Theodore E., Lu, Wentao, Marsigliano, Jessica, Raskob, Gary E., Barnathan, Elliot S.

“…Abstract Background The MARINER trial evaluated whether postdischarge thromboprophylaxis with rivaroxaban could reduce the primary outcome of symptomatic…”
Get full text

Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease by Loza, Matthew J, Watt, Rosemary, Baribaud, Frédéric, Barnathan, Elliot S, Rennard, Stephen I

“…Chronic obstructive pulmonary disease (COPD) is characterized by progressive worsening of airflow limitation associated with abnormally inflamed airways in…”
Get full text